Tag:
omacetaxine mepesuccinate
Latest Headlines
Latest Headlines
ChemGenex scores $138M cancer licensing pact
ChemGenex Pharmaceuticals has scored a $138 million licensing deal with Hospira, which will help market and further develop the Australian biotech's lead cancer drug, omacetaxine mepesuccinate.
